Giorgia Vicentini
Vice President, Program Lead, Oncology Bristol Myers Squibb
Seminars
Wednesday 14th October 2026
Spotlighting the Clinical Performance of Izalontamab Brengitecan Bispecific ADC with First-Line Potential in Metastatic Triple Negative Breast Cancer
4:00 pm
- Breaking down design and development of Iza-Bren, a EGFR/HER3 bispecific ADC, including advantages against traditional monospecific ADC therapies
- Evaluating Iza-Bren clinical profile from BL-B01D1-307 clinical trials with significant, clinical meaningful PFS and OS versus standard chemotherapy in metastatic TNBC
- Laying out ongoing clinical development and first-line mTNBC potential of Iza-Bren through leverage bispecific ADC advantages and impactful clinical profile
